Advances in prodrug design for Parkinson’s disease

References

• Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nat Rev Dis Primer. 2017;3:17013.
   PubMed Web of Science ®Google Scholar
• Kim C, Lee SJ. Controlling the mass action of α-synuclein in Parkinson’s disease. J Neurochem. 2008;107:303–316.
   PubMed Web of Science ®Google Scholar
• Xilouri M, Brekk OR, Stefanis L. Alpha-synuclein and protein degradation systems: a reciprocal relationship. Mol Neurobiol. 2012;47:537–551.
   PubMed Web of Science ®Google Scholar
• Müller MLTM, Bohnen NI. Cholinergic dysfunction in Parkinson’s disease. Curr Neurol Neurosci Rep. 2013;13:9.
   Web of Science ®Google Scholar
• Politis M, Loane C. Serotonergic dysfunction in Parkinson’s disease and its relevance to disability. The Scien World J. 2011;11:1726–1734.
   Google Scholar
• Savica R, Grossardt BR, Bower JH, et al. Incidence and pathology of synucleinopathies and tauopathies related to Parkinsonism. JAMA Neurol. 2013;70:859–866.
   PubMed Web of Science ®Google Scholar
• Kianirad Y, Simuni T. Novel approaches to optimization of levodopa therapy for Parkinson’s disease. Curr Neurol Neurosci Rep. 2016;16:34.
   PubMed Web of Science ®Google Scholar
• LeWitt PA. Levodopa for the treatment of Parkinson’s disease. N Engl J Med. 2008;359:2468–2476.
   PubMed Web of Science ®Google Scholar
• Marsden CD, Parkes JD, Rees JE. A year’s comparison of treatment of patients with Parkinson’s disease with levodopa combined with carbidopa versus treatment with levodopa alone. Lancet. 1973;29 December:1459–1462.
   Google Scholar
• Rinne U, Mölsä P. Levodopa with benserazide or carbidopa in Parkinson disease. Neurology. 1979;29:1584–1589.
   PubMed Web of Science ®Google Scholar
• Brooks DJ, Sagar H. UK-Irish Entacapone Study Group. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson’s disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry. 2003;74:1071–1079.
   PubMed Web of Science ®Google Scholar
• Leegwater-Kim J, Waters C. Role of tolcapone in the treatment of Parkinson’s disease. Expert Rev Neurother. 2007;7:1649–1657.
   PubMedGoogle Scholar
• Ferreira JJ, Lees A, Rocha JF, et al. Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016;15:154–165.
   PubMed Web of Science ®Google Scholar
• Pålhagen S, Heinonen E, Hägglund J, et al. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology. 2006;66:1200–1206.
   PubMed Web of Science ®Google Scholar
• Stocchi F, Arnold G, Onofrj M, et al. Improvement of motor function in early Parkinson disease by safinamide. Neurology. 2004;63:746–748.
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol. 2004;61:561–566.
   PubMed Web of Science ®Google Scholar
• Stocchi F, Hersh BP, Scott BL, et al. Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson’s disease: a randomized, double-blind, non-inferiority crossover study. Curr Med Res Opin. 2008;24:2883–2895.
   PubMed Web of Science ®Google Scholar
• Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:573–580.
   PubMed Web of Science ®Google Scholar
• Brocco M, Dekeyne A, Papp M, et al. Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors. Behav Pharmacol. 2006;17:559–572.
   PubMed Web of Science ®Google Scholar
• Watts RL, Jankovic J, Waters C, et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology. 2007;68:272–276.
   PubMed Web of Science ®Google Scholar
• Katzenschlager R, Hughes A, Evans A, et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson’s disease: a prospective study using single-dose challenges. Mov Disord. 2005;20:151–157.
   PubMed Web of Science ®Google Scholar
• Thomas A, Iacono D, Luciano AL, et al. Duration of amantadine benefit on dyskinesia of severe Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2004;75:141–143.
   PubMed Web of Science ®Google Scholar
• Katzenschlager R, Sampaio C, Costa J, et al. Anticholinergics for symptomatic management of Parkinson’s disease. Cochrane Database Syst Rev. 2002;3:CD003735.
   Google Scholar
• Strang RR. Clinical evaluation of biperiden in Parkinson’s disease. Dis Nerv Syst. 1967;28:191–193.
   PubMedGoogle Scholar
• Gonzalez F. Diphenhydramine may be useful as a palliative treatment for patients dying with Parkinson’s disease and tremors: a case report and discussion. Am J Hosp Palliat Care. 2009;126:474–475.
   Google Scholar
• Schelosky L, Benke T, Poewe WH. Effects of treatment with trihexyphenidyl on cognitive function in early Parkinson’s disease. J Neural Transm Suppl. 1991;33:125–132.
   PubMedGoogle Scholar
• LeWitt PA, Fahn S. Levodopa therapy for Parkinson disease: a look backward and forward. Neurology. 2016;86:S3–S12.
   PubMed Web of Science ®Google Scholar
• Muller T. Catechol-O-methyltransferase inhibitors in Parkinson’s disease. Drugs. 2015;75:157–174.
   PubMed Web of Science ®Google Scholar
• Fox SH, Katzenschlager R, Lim SY, et al. The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2014;26:S2–S41.
   Google Scholar
• Schapira AH. Monoamine oxidase B inhibitors for the treatment of Parkinson’s disease: a review of symptomatic and potential disease-modifying effects. CNS Drugs. 2011;25:1061–1071.
   PubMed Web of Science ®Google Scholar
• Schapira AHV, Stocchi F, Borgohain R, et al. Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson’s disease. Eur J Neurol. 2013;20:271–280.
   PubMed Web of Science ®Google Scholar
• Borgohain R, Szasz J, Stanzione P, et al. Two-Year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson’s disease. Mov Disord. 2014;29:1273–1280.
   PubMed Web of Science ®Google Scholar
• Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. Jama. 2014;311:1670–1683.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Poewe W. Therapies in Parkinson’s disease. Curr Opin Neurol. 2012;25:433–447.
   PubMed Web of Science ®Google Scholar
• Serrano ID, Ribeiro MMB, Castanho MARB. A focus on glucose-mediated drug delivery to the central nervous system. Mini Rev Med Chem. 2012;12:301–312.
   PubMed Web of Science ®Google Scholar
• Salameh F, Karaman D, Mecca G, et al. Prodrugs targeting the central nervous system (CNS). World J Pharm Pharm Sci. 2015;4:208–237.
   Google Scholar
• Pardridge WM. Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv. 2003;3:90–105.
   PubMedGoogle Scholar
• Sozio P, Cerasa LS, Abbadessa A, et al. Designing prodrugs for the treatment of Parkinson’s disease. Expert Opin Drug Discov. 2012;7:385–406.
   PubMed Web of Science ®Google Scholar
• Zawilska JB, Wojcieszak J, Olejniczak AB. Prodrugs: a challenge for the drug development. Pharmacol Reports. 2013;65:1–14.
   PubMed Web of Science ®Google Scholar
• Patruno A, Fornasari E, Di Stefano A, et al. Synthesis of a novel cyclic prodrug of S -allyl-glutathione able to attenuate LPS-induced ROS production through the inhibition of MAPK pathways in U937 cells. Mol Pharm. 2015;12:66–74.
   PubMed Web of Science ®Google Scholar
• Pinnen F, Cacciatore I, Cornacchia C, et al. CNS delivery of L-dopa by a new hybrid glutathione-methionine peptidomimetic prodrug. Amino Acids. 2012;42:261–269.
   PubMed Web of Science ®Google Scholar
• Pavan B, Dalpiaz A, Ciliberti N, et al. Progress in drug delivery to the central nervous system by the prodrug approach. Molecules. 2008;13:1035–1065.
   PubMed Web of Science ®Google Scholar
• Bizzarri BM, Tortolini S, Rotelli L, et al. Current advances in L-Dopa and DOPA-peptidomimetics: chemistry, applications and biological activity. Curr Med Chem. 2015;22:4138–4165.
   PubMed Web of Science ®Google Scholar
• Cacciatore I, Baldassarre L, Fornasari E, et al. (R)-α-lipoyl-glycyl-L-prolyl-L-glutamyl dimethyl ester codrug as a multifunctional agent with potential neuroprotective activities. ChemMedChem. 2012;7:2021–2029.
   PubMed Web of Science ®Google Scholar
• Pinnen F, Cacciatore I, Cornacchia C, et al. Synthesis and study of L-dopa-glutathione codrugs as new anti-Parkinson agents with free radical scavenging properties. J Med Chem. 2007;50:2506–2515.
   PubMed Web of Science ®Google Scholar
• Cacciatore I, Cornacchia C, Fornasari E, et al. A glutathione derivative with chelating and in vitro neuroprotective activities: synthesis, physicochemical properties, and biological evaluation. ChemMedChem. 2013;8:1818–1829.
   PubMed Web of Science ®Google Scholar
• Vlieghe P, Khrestchatisky M. Medicinal chemistry based approaches and nanotechnology-based systems to improve CNS drug targeting and delivery. Med Res Rev. 2013;33:457–516.
   PubMed Web of Science ®Google Scholar
• Peura L, Malmioja K, Huttunen K, et al. Design, synthesis and brain uptake of lat1-targeted amino acid prodrugs of dopamine. Pharm Res. 2013;30:2523–2537.
   PubMed Web of Science ®Google Scholar
• Tutone M, Chinnici A, Almerico AM, et al. Design, synthesis and preliminary evaluation of dopamine-amino acid conjugates as potential D1 dopaminergic modulators. Eur J Med Chem. 2016;124:435–444.
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Ellenbogen A, Chen D, et al. Actively transported levodopa prodrug XP21279. Clin Neuropharmacol. 2012;35:103–110.
   PubMed Web of Science ®Google Scholar
• Atlas D. DopAmide: novel, water-soluble, slow-release l-dihydroxyphenylalanine (l-DOPA) precursor moderates l-DOPA conversion to dopamine and generates a sustained level of dopamine at dopaminergic neurons. CNS Neurosci Ther. 2016;22:461–467.
   PubMed Web of Science ®Google Scholar
• ABBVIE INC. Carbidopa and L-Dopa prodrugs and their use to treat Parkinson disease. WO2016/065019 (2016).
   Google Scholar
• Wang CL, Fan Y-B, Lee SE, et al. Systemic and brain bioavailabilities of D-phenylglycine-L-Dopa, a sustained dopamine-releasing prodrug. J Food Drug Anal. 2013;21:136–141.
   Web of Science ®Google Scholar
• Zhou T, Hider RC, Jenner P, et al. Design, synthesis and biological evaluation of peptide derivatives of l-dopa as anti-parkinsonian agents. Bioorganic Med Chem Lett. 2013;23:5279–5282.
   PubMedGoogle Scholar
• Zhou T, Hider RC, Jenner P, et al. Design, synthesis and biological evaluation of l-dopa amide derivatives as potential prodrugs for the treatment of Parkinson’s disease. Eur J Med Chem. 2010;45:4035–4042.
   PubMed Web of Science ®Google Scholar
• Liu KS, Sung KC, Al-Suwayeh SA, et al. Enhancement of transdermal apomorphine delivery with a diester prodrug strategy. Eur J Pharm Biopharm. 2011;78:422–431.
   PubMed Web of Science ®Google Scholar
• Liu K-S, Wen C-J, Yen T-C, et al. Combined strategies of apomorphine diester prodrugs and nanostructured lipid carriers for efficient brain targeting. Nanotechnology. 2012;23:95103.
   Web of Science ®Google Scholar
• Borkar N, Li B, Holm R, et al. Lipophilic prodrugs of apomorphine I: preparation, characterisation, and in vitro enzymatic hydrolysis in biorelevant media. Eur J Pharm Biopharm. 2015;89:216–223.
   PubMed Web of Science ®Google Scholar
• Borkar N, Chen Z, Saaby L, et al. Apomorphine and its esters: differences in Caco-2 cell permeability and chylomicron affinity. Int J Pharm. 2016;509:499–506.
   PubMedGoogle Scholar
• Borkar N, Andersson DR, Yang M, et al. Efficacy of oral lipid-based formulations of apomorphine and its diester in a Parkinson’s disease rat model. J Pharm Pharmacol. 2017;69:1110–1115.
   PubMed Web of Science ®Google Scholar
• Fernández M, Barcia E, Fernández-Carballido A, et al. Controlled release of rasagiline mesylate promotes neuroprotection in a rotenone-induced advanced model of Parkinson’s disease. Int J Pharm. 2012;438:266–278.
   PubMed Web of Science ®Google Scholar
• Northera (droxidopa). Full prescribing information. Deerfield, IL: Lundbeck NA Ltd; 2014.
   Google Scholar
• Goldstein DS, Holmes C, Sewell L, et al. Effects of carbidopa and entacapone on the metabolic fate of the norepinephrine prodrug L-DOPS. J Clin Pharmacol. 2011;51:66–74.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Hewitt LA, Isaacson S. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson’s disease (NOH306A). J Parkinsons Dis. 2014;4:57–65.
   PubMedGoogle Scholar
• Hauser RA, Heritier S, Rowse GJ, et al. Droxidopa and reduced falls in a trial of Parkinson disease patients with neurogenic orthostatic hypotension. Clin Neuropharmacol. 2016;39:220–226.
   PubMed Web of Science ®Google Scholar
• Biaggioni I, Arthur Hewitt L, Rowse GJ, et al. Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension. BMC Neurol. 2017;17:90.
   PubMed Web of Science ®Google Scholar
• Santerre JL, Nunes EJ, Kovner R, et al. The novel adenosine A2A antagonist prodrug MSX-4 is effective in animal models related to motivational and motor functions. Pharmacol Biochem Behav. 2012;102:477–487.
   PubMed Web of Science ®Google Scholar
• Eskow Jaunarajs KL, Standaert DG, Viegas TX, et al. Rotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefit. Mov Disord. 2013;28:1675–1682.
   PubMed Web of Science ®Google Scholar
• Biswas S, Hazeldine S, Ghosh B, et al. Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly potent and selective agonists for dopamine D3 receptor with potent in vivo activity. J Med Chem. 2008;51:3005–3019.
   PubMed Web of Science ®Google Scholar
• Dholkawala F, Voshavar C, Dutta AK. Synthesis and characterization of brain penetrant prodrug of neuroprotective D-264: potential therapeutic application in the treatment of Parkinson’s disease. Eur J Pharm Biopharm. 2016;103:62–70.
   PubMed Web of Science ®Google Scholar